(Reuters) - Cipla Ltd, India's third-largest drugmaker by market capitalisation, posted on Wednesday a more than 10 percent rise in its first-quarter profit, well above analysts' expectations.
Net profit came in at 4.51 billion rupees ($65.67 million) in the three months ended June 30, compared with 4.09 billion rupees a year ago, the company said in a statement https://www.bseindia.com/xml-data/corpfiling/AttachLive/cd22e4bc-c6ea-4b53-b09b-2bfff73549e9.pdf.
Analysts on average had expected a profit of 3.91 billion rupees, Thomson Reuters Eikon data showed.
Net sales jumped 12 percent to 38.46 billion rupees.
($1 = 68.6725 Indian rupees)
Also Read
(Reporting by Krishna V Kurup in Bengaluru, Editing by Sherry Jacob-Phillips)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app